RECENT NEWS
Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars
Pfizer just had a big setback in its race for an Ozempic competitor
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump